Burroughs Valentine J, Maxey Randall W, Levy Richard A
Health Policy Committee, Board of Trustees, National Medical Association, Washington, DC, USA.
J Natl Med Assoc. 2002 Oct;94(10 Suppl):1-26.
It is now well documented that substantial disparities exist in the quality and quantity of medical care received by minority Americans, especially those of African, Asian and Hispanic heritage. In addition, the special needs and responses to pharmaceutical treatment of these groups have been undervalued or ignored. This article reviews the genetic factors that underlie varying responses to medicines observed among different ethnic and racial groups. Pharmacogenetic research in the past few decades has uncovered significant differences among racial and ethnic groups in the metabolism, clinical effectiveness, and side-effect profiles of many clinically important drugs. These differences must be taken into account in the design of cost management policies such as formulary implementation, therapeutic substitution and step-care protocols. These programs should be broad and flexible enough to enable rational choices and individualized treatment for all patients, regardless of race or ethnic origin.
现在有充分的文献记载,美国少数族裔,尤其是非洲、亚洲和西班牙裔血统的人,在接受医疗护理的质量和数量上存在巨大差异。此外,这些群体的特殊需求以及对药物治疗的反应一直被低估或忽视。本文回顾了不同种族和民族群体对药物反应不同的潜在遗传因素。过去几十年的药物遗传学研究发现,在许多临床重要药物的代谢、临床疗效和副作用方面,不同种族和民族群体之间存在显著差异。在制定成本管理政策时,如药品目录实施、治疗替代和阶梯治疗方案,必须考虑到这些差异。这些方案应该足够广泛和灵活,以便为所有患者提供合理的选择和个性化治疗,无论其种族或族裔出身如何。